Business
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
HOUSTON, May 13, 2025--Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical- stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the first quarter ended March 31, 2025, and provided a business update.
About this update from Tvardi Therapeutics, Inc.
[{"type":"text","content":"Completed merger with Cara Therapeutics; cash, cash equivalents and short-term investments at closing anticipated to be sufficient to fund operations into 2H 2026","length":162,"tagName":"p","attribs":{}},{"type":"text","content":"On track for multiple Phase 2 data readouts with STAT3 inhibitor, TTI-101, with lead program in IPF expected in 2H 2025","length":119,"tagName":"p","attribs":{}},{"type":"text","content":"HOUSTON, May 13, 2025--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical- stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the first quarter ended March 31, 2025, and provided a business update.","length":392,"tagName":"p"},{"type":"text","content":"First Quarter 2025 and Subsequent Period Highlights:","length":52,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Tvardi completed its merger with Cara Therapeutics.","length":51,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Tvardi received approximately $23.8 million in net cash from Cara in connection with the closing of the merger. This capital augments the previously announced December 2024 private placement financing of approximately $28.3 million from a syndicate of new and existing institutional investors.","length":292,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":292,"olType":false}]},{"val":[{"type":"text","content":"Announced that an abstract, entitled, Single Cell Transcriptomics in A Treatment Status Segregated Cohort Exposes a STAT-3-Regulated Therapeutic Gap in Idiopathic Pulmonary Fibrosis, will be presented at the upcoming American Thoracic Society 2025 Annual Conference, which is being held May 16-21, 2025 in San Francisco.","length":320,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced that results from the first-in-human Phase 1 study of TTI-101 in patients with advanced solid tumors were published in the journal Clinical Cancer Research.","length":165,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":828,"olType":false},{"type":"text","content":"Dr. Imran Alibhai, Chief Executive Officer of Tvardi, stated, "While i...